Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637052 · ClinicalTrials.gov registry record · Phase 1
A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00637052 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 36 participants.
The verdict
NCT00637052, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a 2-phase study during which patients with select myeloid leukemias or advanced myelodysplastic syndrome (MDS), who have failed, refused or are not eligible for standard treatment, will receive investigational study drug ARRY-520. The study has 3 parts. The first phase of the study, Phase 1, has 2 parts. In the first part of Phase 1, patients with select myeloid leukemias or advanced MDS will receive increasing doses of study drug on different schedules in order to achieve the highest dose possible that will not cause unacceptable side effects. Approximately 30 patients (per schedule) from the US will be enrolled in Part 1 (Completed). In the second part of Phase 1, patients with advanced MDS will receive the best dose of study drug and schedule determined from the first part of the study. Approximately 10 patients from the US will be enrolled in Part 2 (Completed). In the third part of the study, Phase 2, patients with acute myeloid leukemia (AML) or advanced MDS will receive the best dose of study drug and schedule determined from the first part of the study and will be followed to see what side effects the study drug causes and to see what effectiveness it has, if any, in treating the cancer. Approximately 40 patients from the US will be enrolled in Part 3 (Withdrawn).
Interventions
- DRUG ARRY-520, KSP(Eg5) inhibitor; intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-03-18 |
| Est. Completion | 2010-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637052
The ClinicalTrials.gov registry entry for NCT00637052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARRY-520, KSP(Eg5) inhibitor; intravenous is the first listed.
NCT00637052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637052 about?
NCT00637052 is a clinical study titled "A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia". This is a 2-phase study during which patients with select myeloid leukemias or advanced myelodysplastic syndrome (MDS), who have failed, refused or are not eligible for standard treatment, will receive investigational study drug ARRY-520. The study has 3 parts. The first phase of the study, Phase 1...
What is the current status of trial NCT00637052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-03-18. Estimated completion is 2010-06-21.
What interventions are being tested in trial NCT00637052?
The interventions under investigation include: ARRY-520, KSP(Eg5) inhibitor; intravenous (DRUG).
Who is sponsoring clinical trial NCT00637052?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.